Clinical trial
Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection.
NCT04467671 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection.
- Lead sponsor
- Nationwide Children's Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 15, 2020
- Completion date
- August 31, 2027
- Enrollment
- 24 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cardiovascular abnormalities, cardiovascular diseases, dilv - double inlet left ventricle, dorv, heart defects, congenital, heart diseases, hlh - hypoplastic left heart syndrome, mitral atresia, single-ventricle, tricuspid atresia, unbalanced av canal